



Periodontal diseases are initiated by Gram-negative tooth-
associated microbial biofilms that elicit a host response, with
resultant osseous and soft tissue destruction. In response to
endotoxins derived from periodontal pathogens, several oste-
oclast-related mediators target the destruction of alveolar
bone and supporting connective tissues. Major drivers of this
aggressive tissue destruction are matrix metalloproteinases
(MMPs), cathepsins, and other osteoclast-derived enzymes.
This article focuses on the downstream factors of the osteo-
clast responsible for the degradation of bone and soft tissues
around teeth and oral implants. Furthermore, therapeutic
approaches that target MMP-2, -8, and -9 inhibition, such as
MMP inhibitors, chemically modified tetracyclines, and sub-
antimicrobial formulations of tetracycline analogues, are dis-
cussed. The use of rapid, chair-side tests of MMP activity, in
particular for MMP-8 and bone collagen fragments, show
strong potential as non-invasive measures of tissue health or
disease. In addition, studies using other agents for the preser-
vation of bone mass, such as bisphosphonates that inhibit os-
teoclast recruitment, are highlighted. The application of these
bone-preservation strategies to periodontal management and
treatment are discussed in the context of high-risk patients
susceptible to disease reactivation or disease complications.
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P
eriodontal diseases, which cause
the destruction of the supporting
structures of the dentition, are com-
mon chronic infectious diseases of the
oral cavity. They are initiated by Gram-
negative tooth-associated pathogens
organized as a biofilm, whose presence
elicits a host inflammatory response.
Although gingivitis represents the re-
versible inflammatory reaction to bio-
films, periodontitis is the non-reversible
destructive stage of a persistent bacte-
rial infection. If left untreated, periodon-
titis results in soft tissue and progressive
bone destruction and leads to tooth mo-
bility and subsequent tooth loss.1 Re-
cently, there has been a great deal of
basic and clinical research focusing on
the underlying mechanisms of the major
enzymatic drivers of this aggressive tissue
destruction. Along with briefly discuss-
ing the pathology of chronic periodon-
titis and its main players, this article
focuses on promising therapeutic agents
for the tissue destruction of periodonti-
tis; i.e., using matrix metalloproteinase
(MMP) inhibitors as host modulatory
agents, and bisphosphonates as blockers
of tooth-supporting alveolar bone de-
struction. Together, improved apprecia-
tion of such therapeutic strategies may
ultimately lead to a more individualized
targeted treatment for a disease of which
31% of the United States population
exhibits mild forms, 13% display mod-
erate severity, and 4% have advanced
disease symptoms.2
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Acting as the prototypical endotoxin, lipopolysac-
charides (LPS), a major component of the outer mem-
brane of Gram-negative bacteria, initiate the cascade
of events leading to periodontal tissue destruction.1
Briefly, LPS derived from plaque biofilms on the tooth
root surface lead to the recruitment of polymorphonu-
clear leukocytes (PMNs) to the site. Monocytes and
activated macrophages respond by releasing various
proinflammatory cytokines, including interleukin (IL)-
1b and tumor necrosis factor (TNF)-alpha, which, in
turn, direct further destructive processes. Along with
cathepsins and other osteoclast-derived mediators
of bone resorption, one group of powerful endopepti-
dases released by fibroblasts and PMNs at this stage is
MMPs. Specific members of the MMP family have be-
come attractive targets for therapeutic intervention.
As such, it is worth examining their physiological
functions in greater detail, because their role in perio-
dontitis is complex.
MMPs: Tissue destruction and beyond
Proteolytic enzymes are implicated in a number of
processes in normal bone remodeling, including bone
resorption and bone formation.3 The activity of oste-
oclast-secreted proteolytic enzymes, such as the
MMPs, is essential to normal bone homeostasis. Such
MMPs are responsible for the destruction of mineral-
ized tissue during bone resorption. In contrast, osteo-
blasts also secrete MMPs that degrade the non-
mineralized osteoid layer on the surface of bone.3
The MMP multigene family encodes 22 structurally
related endopeptidases with activity against most ex-
tracellular matrix, pericellular, and non-matrix macro-
molecules.4 As components of the greater human
‘‘degradome,’’ they can be divided into a number of
subclasses according to their substrate specificities
and physical structure: interstitial collagenases, gela-
tinases, membrane-type MMPs, and other MMPs that
include stromelysins and metalloelastases (Fig. 1).
MMPs play key roles in the degradation of various ex-
tracellular molecules, including collagen, elastin, pro-
teoglycans, and laminins.5 Although beyond the scope
of this article, it is worth noting that MMPs have other
significant roles in wound healing and immunity, in
the pathology of tumor progression in cancer, and in
fibrosis.3,6 A role thathas been consideredofgreat clin-
ical importance in periodontitis is the ability of MMPs to
activate latent forms of effector proteins, such as anti-
microbial peptides, chemokines, and cytokines, as
well their role in altering protein function, such as shed-
dingofcell-surface proteins.6 Thereare a greatnumber
of chemokines that are proteolytically processed by
various MMPs during wound healing and inflammation,
resulting in subsequent modifications to chemokine
function(Table1).Forexample,MMP-8 isacriticalme-
diator initiating LPS responsiveness in vivo. MMP-8
cleaves LPS-induced CXC chemokine (LIX). PMN-
derived MMP-8 cleaves and activates LIX to execute
an in cis PMN-controlled feed-forward mechanism to
Figure 1.
Distribution of proteases in the human degradome involved in tumorogenesis, wound repair, and tissue destruction. A gray line indicates each individual
enzyme, and those with tumor-protective properties are shown in red. Numbers at the edge represent different protease families of each catalytic class
according to MEROP database numbering. Adapted with permission from Macmillian Publishers, copyright 2007.9
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orchestrate the initial inflammatoryresponseandpromote
LPS responsiveness in periodontal tissue.7 These pro-
cesses may include complete degradation of the che-
mokine, the creation of receptor antagonists, or the
stimulation of dramatic increases in chemokine ac-
tivity.8 Regardless, because MMPs can govern the
activity of various effectors and other biologically ac-
tive molecules by methods such as direct cleavage or
by modification or inactivation of their inhibitors, they
can be considered host-modulatory agents.4 As such,
and depending on the tissue, its complexity, and the
exposure to particular pathogens, these actions have
great implications on disease progression. For exam-
ple, in tumor progression, various MMPs directly or
indirectly have key roles during growth, survival, an-
giogenesis, invasion, inflammation, and repair.9 As a
result, in part, of this functional complexity, long-term
therapies that have been developed to block the activ-
ity of MMPs during the progression of cancer havegen-
erally failed in the clinic. Nonetheless, because MMPs
remain among the key mediators of irreversible tissue
destruction in periodontitis, a study10 was undertaken
that examined their potential as a biomarker, and thus
as a modulator, of disease progression.
MMPs as biomarkers of periodontal diseases
The number of publications investigating the role of
MMPs in periodontal disease progression and expres-
sion continue to grow. Similar to the
use of collagen telopeptide frag-
ments, such as pyridinoline cross-
linked carboxyterminal telopeptide
of type I collagen (ICTP), as bio-
markers of bone degradation,11 a re-
cent focus has been on the diagnostic
usefulness of measuring levels of
MMPs as a biomarker of periodontal
severity and as a response to therapy
(Fig. 2).1 Of the several biomarkers
that have been studied, one of the
strongest potential candidates in
point-of-care (POC) tests is MMP-8,
the most prevalent MMP in diseased
periodontal tissue and saliva.11 Re-
cently, a portable diagnostic device
has been developed (based on the
principle of rapid saliva diagnosis at
the POC) called the Integrated Micro-
fluidic Platform for Oral Diagnostics
(IMPOD).12 An early clinical study13
in which the hand-held IMPOD rap-
idly (3 to 10 minutes) measured the
concentrations of MMP-8 and other
biomarkers in small amounts (10
ml) of saliva was reported. The mean
MMP-8 concentration in the saliva of
the periodontally healthy individuals was 10-fold less
than that of the periodontally diseased patients. Thus,
the use of such immunoassay technologies in mea-
suring a putative biomarker of periodontal disease
in saliva may permit rapid accurate POC diagnoses,
dynamic monitoring of disease activity, and poten-
tially a more effective treatment.12 Clearly, MMPs are
promising candidates for predicting, diagnosing,
and, possibly more importantly, assessing the pro-
gression of this episodic disease.1,13 Furthermore,
the use of rapid, chair-side tests of MMP activity
showed strong potential as a non-invasive measure
of tissue health or disease, because MMPs are clearly
associated with progressive periodontitis.14
POTENTIAL THERAPEUTIC STRATEGIES IN
PERIODONTAL DISEASE
After considering the role of MMPs in periodontal dis-
ease, it is clear that agents that directly or indirectly
block the activity of active osteoclasts may represent
potential ‘‘bone-sparing’’ therapies. There are many
potential therapeutic targets during the progression
of periodontal lesions, from the prestimulated mono-
cyte to the postactivated osteoclast, along with the
multitude of cytokines produced by these cells (Fig.
3).15 The unifier of these potential targets is their
shared role in the inflammatory response, which has
Table 1.
Chemokines Are Proteolytically Processed by MMPs
During Wound Healing and Inflammation
Reprinted with permission from Elsevier.8
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led to the concept of host modulation. Patients with
systemic diseases, such as diabetes and cardiovascu-
lar diseases, share links between biomarkers of sys-
temic inflammation and periodontitis and, thus, are
believed to be at high-risk for periodontal disease, be-
cause systemic inflammation is proposed to coinduce
periodontal tissue destruction in concert with micro-
bial-secreted LPS.16
First described by Golub et al.17 and later expanded
byWilliams,18 researchon theprotectiveeffectsofcom-
mon non-steroidal anti-inflammatory drugs (NSAIDs)
and tetracyclines led to the concept of host modula-
tion as a therapy for the cessation of periodontitis pro-
gression. Rheumatoid arthritis represents an example
of a disease through which an understanding of po-
tential therapeutic strategies for periodontitis has
occurred.19 The various commonalities in terms of
genesis and progression of the two diseases allow
for direct comparisons of the juncture points for block-
ing downstream molecules, including PMNs, macro-
phages, and MMPs. Partly as a result of these types
of comparisons, a variety of host-modulatory thera-
pies for periodontitis now include the aforementioned
NSAIDs; proteinase inhibitors; such as doxycyclines;
MMP inhibitors; anabolics, such as parathyroid hor-
mone; TNF antagonists; and a variety of antiresorp-
tive agents represented by the bisphosphonates.15
However, when focusing on the bone-destroying ac-
tivity of the osteoclast, the bisphosphonates and
MMP inhibitors deserve additional discussion.
Inhibition of MMPs
Periodontal disease is generally characterized by an
increased presence of subgingival Gram-negative mi-
croorganisms resulting in increased secretion of en-
dotoxin, which ultimately leads to increased gingival
collagenase activity, collagen destruction, and subse-
quent connective tissue destruction and bone loss.
Currently, clinical therapy inhibiting the mediators
of connective tissue breakdown is used for the adjunc-
tive treatment of periodontitis. This is accomplished
through the non-antimicrobial activities of low-dose
tetracycline and tetracycline analogs via the inhibition
of MMP-8 and -13 protease mechanisms.20 The tetra-
cycline analog doxycycline hyclate,‡ available for use
specifically in periodontal disease, is the only colla-
genase inhibitor approved by the United States Food
and Drug Administration (FDA) for any human dis-
ease.10 To clarify, because the low-dose formulations
of these drugs have lost their antimicrobial activity,20
the therapeutic action witnessed is due primarily to
the modulation of the host response. This subantimi-
crobial-dose doxycycline (SDD) approach has be-
come widely established as an effective adjunctive
systemic therapy in the management of periodontitis,
along with the traditional mechanical therapies of
scaling and root planing (SRP). For example, initial
Phase III clinical trials21 of MMP inhibition by SDD in
subjects with periodontal disease over a 6-month pe-
riod led to maintained alveolar bone height compared
to bone height loss with placebo (as measured by sub-
traction radiography). In another early clinical study,22
the efficacy and safety of SDD were evaluated in con-
junction with SRP in subjects with chronic periodonti-
tis. Here, the more severe the periodontitis, the greater
the observed attenuation of disease activity by SDD
therapy (Fig. 4). In a recent systematic review,23
the effectiveness of SRP accompanied by MMP inhibi-
tion (by SDD), as an adjunctive treatment, showed
improved outcomes that persisted for ‡9 months in
adults with chronic periodontitis as observed in gains
in clinical attachment level (CAL) and probing depth
(PD) reduction. Most recently, in a double-masked,
randomized, placebo-controlled, multicenter study24
Figure 2.
Schematic overview of the key biomarkers related to periodontal
disease progression. Initial events are triggered by LPS from Gram-
negative plaque biofilms on the periodontal tissues. As a first line of
defense, PMNs are recruited to the site. Monocytes and activated
macrophages respond to endotoxin by releasing cytokines (TNF and
IL-1) that direct further destruction processes. MMPs, which can act
as powerful collagen-destroying enzymes, are produced by fibroblasts
and PMNs. TNF, IL-1, and receptor activator of nuclear factor-kappa
B ligand (RANKL) are elevated in active sites and mediate
osteoclastogenesis and bone breakdown. Bone-specific markers,
such as ICTP, are released into the surrounding area and transported
by way of gingival crevicular fluid into the sulcus or pocket and serve
as potential biomarkers for periodontal disease detection. Adapted
with permission from Blackwell Publishing.1
‡ Periostat, Galderma Labs, Fort Worth, TX.
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of 266 subjects with periodontal disease, those individ-
uals treated with a modified-release SDD formulation
taken once daily as an adjunct to SRP displayed sig-
nificantly greater clinical benefits (improved CAL gain
and PD reduction) than individuals treated with SRP
alone.
There have been other therapeutic approaches that
involve SDD in the treatment of periodontitis. Notably,
a recent proof-of-principle study25 was designed to ex-
amine aspects of the biologic response brought on by
SDD combined with access flap surgery (AFS) on the
modulation of periodontal wound repair in subjects
with severe periodontitis who were not candidates for
regenerative therapy. Briefly, the periodontal surgery
aimed to remove the microbial biofilm and improve
the host environment, in concert with the SDD modifi-
cation of the host inflammatory response. Together,
the goal is augmentation of periodontal wound healing
(through improving CAL and PD), increased bone sta-
bilization, and decreased MMP expression. The results
of this investigation demonstrated
that SDD, in combination with
AFS, may improve the response to
surgical therapy during drug dosing
by reducing PD in cases of severe
periodontitis compared to AFS
alone (Fig. 5).25 SDD tended to re-
duce post-surgical bleeding on
probing (BOP), PD, and periodontal
bone resorption during drug ad-
ministration, yet it did not affect
the periodontal microflora beyond
the contribution of surgery alone.
Of interest, other accumulating
evidence demonstrated the ability
of MMP inhibitors to be used in the
management of periodontal disease
in patients with decreased bone
mass (as in the situation of post-
menopausal osteoporosis). Recent
studies26,27 demonstrated the abil-
ity of SDD to be used to maintain
bone mass while reducing periodon-
taldiseaseprogression.Furthermore,
oral fluid–derived (i.e., gingival cre-
vicular fluid) biomarkers, such as
collagen telopeptide fragments,
were reduced in subjects following
SDD dosing.28
Although there is strong evi-
dence to suggest that inhibition of
MMPs in patients with periodontal
disease clearly offers potential in
disease management when cou-
pled with mechanical therapy, such
as SRP, there is only preliminary
evidence available to suggest the value of MMP inhib-
itory therapies for patients with peri-implant disease
or in those conditions requiring surgical manage-
ment.23,25 However, a number of questions need to
be answered as the management of periodontitis de-
velops. For example, considering these are chronic
conditions and the role of MMPs in bone homeostasis
and cancer, what are the long-term consequences of
extended MMP inhibition in patients? Also, what are
the downstream-extended effects on controlling cyto-
kine processing, especially concerning the role of de-
creasing MMP-8 activity over time? Perhaps through
the development of more selective MMP inhibitors
for periodontal treatment (to reduce potential side
effects) and by examining combination therapy ap-
proaches considering antimicrobial and host re-
sponse targets, we may make further inroads into
answering these questions. Encouragingly, a survey
of the recent trends in scientific publications suggest
a continued interest in understanding the role of MMPs
Figure 3.
Potential therapeutic strategies to treat bone resorption: agents that block the differentiation or
activity of osteoclasts are potential therapeutic agents. Osteoprotegerin (OPG) inhibits the
differentiation of osteoclasts through its action as a decoy receptor that blocks receptor activator
of nuclear factor-kappa B (NF-kB) ligand (RANKL) and RANK juxtacrine interaction. Non-steroidal
anti-inflammatory drugs (NSAIDs) and other anti-inflammatory molecules (including p38
mitogen-activated protein kinase inhibitors, c-jun N-terminal kinase inhibitors, NF-kB inhibitors,
and the specific, high-affinity IL-1 inhibitor IL-1 [TRAP]) can inhibit the formation of hemato-
progenitor cells to preosteoclasts. Antibodies to RANKL can also block this interaction. MMP
inhibitors reduce the protease degradation of the organic matrix, and anti-integrins block the initial
osteoclast adhesion to the matrix. Bisphosphonates and MMP inhibitors work at the site of the
osteoclast adhesion zone to the mineralized matrix in blocking bone resorption. M-CSF =
macrophage colony-stimulating factor; sRANKL = soluble RANKL; TNFsRC = TNF soluble receptor.
Adapted with permission from Blackwell Publishing.15
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in normal bone homeostasis and periodontal dis-
eases, as well as in other pathologies, particularly tu-
mor metabolism and metastasis. Such continued
investigations on MMPs suggest that many of these
unanswered questions are being addressed.29
Bisphosphonates as bone-sparing agents
Bisphosphonate drugs have well-characterized mod-
ulatory roles on osteoclast function and bone metab-
olism.30 Notably, at the tissue level, they decrease
bone turnover by decreasing bone resorption and by
reducing the number of new bone multicellular units.
At the cellular level, they decrease osteoclast and os-
teoblast recruitment, decrease osteoclast adhesion,
and decrease the release of cytokines by macro-
phages (Table 2). Based on these properties, several
generations of oral bisphosphonate drugs have been
successfully developed for the treatment of postmen-
opausal osteoporosis, osteopenia, and Paget’s dis-
ease of bone.31 Because of these same properties, a
possible use for this class of drugs in the management
of periodontal disease was put forth.30
A few clinical studies have been performed to ex-
amine a possible use for bisphosphonates in the man-
agement of periodontal bone loss.23 In a study32 of 40
subjects with chronic periodontitis, a statistically sig-
nificant decrease in the












studies support the as-
sertion that bisphospho-
nates may be useful as a
host modulator in peri-
odontal disease. A more
recent, larger 12-month
clinical study35 echoed
this contention; 70 sub-










as measured by standardized radiography. Despite
this, bisphosphonate therapy improved CAL, PD,
and BOP over the course of the study, providing some
evidence that bisphosphonate may be an appropriate
adjunctive therapy to preserve periodontal support
Figure 4.
MMP inhibition reduces disease activity in patients with severe
periodontitis. Effect of SDD on clinical attachment loss ‡2 mm from
baseline to 9 months. Tooth sites were stratified by degree of disease
severity, based on PD at baseline. Mean per-patient percentages
(– SE) are presented. The more severe the disease state, the greater
the observed attenuation of disease activity by SDD therapy. Adapted
from reference 22.
Figure 5.
Effect of subantimicrobial-dose doxycycline (SDD) or placebo in combination with surgery on clinical parameters
and ICTP for initial pocket ‡7 mm. The bars represent per-patient standard errors. P values indicate significant
changes over time within a treatment as determined by the Quade test. Adapted from reference 25.
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over time. However, overall, only limited informationex-




Bisphosphonates are administered by intravenous (IV)
infusion (in the case of treatment for metastatic bone
cancers) or orally (for the treatment of decreased bone
density in osteoporosis). Because of a significant rate
of non-compliance and the subsequent decrease in
clinical efficacy, IV bisphosphonate delivery has been
used extensively for malignant bone diseases, as well
as in breast, prostate, and lung cancer.36 However, a
number of publications documented the retrospective
reports associating IV bisphosphonate delivery and
osteonecrosis of the jaws (ONJ).36-38 Clinically, ONJ
is essentially exposed bone in the maxilla or mandible
that does not heal within 8 weeks
of identification by health care
professionals (HCPs). ONJ is
hypothesized to be due to the
disruption of the resorption–
remodeling cycle of bone
inhibitionof endothelial cell pro-
liferation caused by high-dose IV
administration of bisphospho-
nates. The resulting poor healing
and secondary infections lead to
tooth and bone segment loss. A
recent report by the American




risk factors, diagnostic imaging, and clinical manage-
ment (Table 3).38 Based on its review of the available
data on the ranges of ONJ incidence, the ASBMR
report concluded that a risk for ONJ is associated with
oral bisphosphonate therapy for osteoporosis in less
than one in 100,000 patients. However, a much higher
risk for ONJ was associated with high-dose IV
bisphosphonate therapy in patients with cancer and
was reported to be in the range of one to 10 per 100
patients, increasing depending on therapy duration.
Although there are few reports specifically on ONJ in
periodontal patients, dental professionals have been
made aware of the potential adverse effects in their
patients under IV bisphosphonate treatment for other
bone diseases or cancer. In a study37 that reported nine
cases of ONJ in periodontal patients, all nine patients
had a history of extractions of periodontally hopeless
teeth preceding the onset of ONJ. Along with a predi-
lection for the disease in the mandible, the duration of
IV bisphosphonate therapy at presentation ranged
from >5 years to as short as 10 months. Of further in-
terest to those HCPs treating patients on oral bisphos-
phonates is one particular case report36 describing
how a patient who had been taking oral bisphospho-
nates for osteoporosis for >10 years developed unex-
plained clinical signs of bone necrosis after routine
dental implant placement. Briefly, the report noted
compromised healing was successfully treated with
systemic antibiotics, local microbial mouthrinse, and
aggressive defect management via detoxification and
a mixture of bone graft and tetracycline. This suggests
that dental HCPs should treat patients undergoing





ONJ provided a host of treatment recommendations
Table 2.
Activities of Bisphosphonates on Osteoclast Function at the
Tissue, Cellular, and Molecular Levels
Tissue Level Cellular Level Molecular Level
Y bone turnover due to
Y bone resorption







Y depth of resorption site





(can result in perturbated




GTP = guanosine triphosphate.
Adapted from reference 30.
Table 3.
Treatment Recommendations for Patients
With Osteoporosis Receiving
Bisphosphonate Therapy
Patients informed of risks
Oral hygiene and dental care emphasized
Not necessary to require dental examination prior to
bisphosphonate therapy or alter dental management
For patients on bisphosphonates >3 years:
Periodontal disease treatment non-surgically or conservative
surgical therapy
Dental-implant placement with informed consent
Endodontic treatment preferable to extraction or periapical
surgery
For invasive procedures, a drug vacation may be helpful but has
not been validated
Adapted with permission from the American Society for Bone and Mineral
Research.38
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for patients with osteoporosis (Table 3).38 Informing
patients of the ONJ risks involved at the initiation
of bisphosphonate treatment was recommended,
coupled with an emphasis on the importance of good
oral hygiene and dental care. The investigators did not
deem it necessary for these patients to have a dental
examination prior to treatment initiation or to alter
their dental management during the treatment. In par-
ticular, for those patients on bisphosphonate for >3
years, recommendations included an encouragement
for non-surgical or conservative surgical periodontal
disease treatment; dental implant placement with
informed consent; and a preference for endodontic
treatment over extraction or periapical surgery. For
invasive procedures, such as grafting, anecdotal evi-
dence suggests that a drug vacation may be helpful
given the long-term sequestration of bisphospho-
nates in bone for up to 10 years or longer.38 In a similar
vein, the FDA provided recommendations39 to dental
practitioners regarding the treatment of patients pre-
senting with ONJ that the American Academy of Peri-
odontology has incorporated into its own guidance.40
The recommendations of this mostly palliative ap-
proach include non-surgical approaches in the oral
cavity, as well as bony debridement to reduce sharp
edges, both to prevent further osseous injury; protec-
tive stents in areas of exposed bone; biopsy per-
formed only if metastasis to the jaw is suspected;
the initiation of antibiotic therapy (topical and sys-
temic); and frequent monitoring of these patients.
Overall, the use of bisphosphonates for the man-
agement of periodontal diseases has limited promise,
especially in affecting alveolar bone loss. However,
despite their different mode of action, additional stud-
ies are needed to evaluate their potential as alveolar
bone–sparing agents.23 Considerations related to
the duration of use are relevant, given the reported
risks associated with ONJ related to the long-term use
of high-dose bisphosphonates, contrasting the poten-
tial benefits of the short-term oral use of these drugs.
Despite progression in this area of research and a bet-
ter understanding of the reported risks, a number of
questions for future consideration of bisphosphonates
in the treatment of periodontal diseases remain, which
should be addressed.
CONCLUSIONS
There has been a great deal of basic and clinical re-
search focusing on the underlying mechanisms of
the major enzymatic drivers of the aggressive tissue
destruction found in periodontitis. Major drivers of this
damage are MMPs, cathepsins, and other osteoclast-
derived mediators of bone resorption, all of which act
as part of the host inflammatory response. Modifica-
tion of this host response via the use of MMP inhibitors,
along with the use of bisphosphonates as blockers of
periodontal tissue destruction, has shown promise in
the therapeutic treatment of these disease states. Al-
though questions remain regarding optimizing treat-
ment efficacy while limiting any potential adverse
effects, the evidence clearly suggests a strong poten-
tial for the modulation of the host response in aiding
disease management, when coupled with traditional
mechanical therapy.
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